4.5 Article

The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway

期刊

CELL CHEMICAL BIOLOGY
卷 25, 期 9, 页码 1117-+

出版社

CELL PRESS
DOI: 10.1016/j.chembiol.2018.06.004

关键词

-

资金

  1. Medical Research Council UK [MC_UU_12016/5]
  2. Division of Signal Transduction Therapy (DSTT) (Boehringer-Ingelheim)
  3. Division of Signal Transduction Therapy (DSTT) (GlaxoSmithKline)
  4. Division of Signal Transduction Therapy (DSTT) (Merck KGaA)
  5. MRC [MC_UU_12016/5] Funding Source: UKRI

向作者/读者索取更多资源

Due to their role in many diseases, enzymes of the ubiquitin system have recently become interesting drug targets. Despite efforts, primary screenings of compound libraries targeting E2 enzymes and E3 ligases have been strongly limited by the lack of robust and fast high-throughput assays. Here we report a label-free high-throughput screening assay for ubiquitin E2 conjugating enzymes and E3 ligases based on MALDI-TOF mass spectrometry. The MALDI-TOF E2/E3 assay allows testing E2 enzymes and E3 ligases for their ubiquitin transfer activity, identifying E2/E3 active pairs, inhibitor potency and specificity and screening compound libraries in vitro without chemical or fluorescent probes. We demonstrate that the MALDI-TOF E2/E3 assay is a universal tool for drug discovery screening in the ubiquitin pathway as it is suitable for working with all E3 ligase families and requires a reduced amount of reagents, compared with standard biochemical assays.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据